Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE OF THE COMPANY DATED NOVEMBER 10, 2016 - MABVAX THERAPEUTICS HOLDINGS, INC. | ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
report (Date of earliest event reported): November 10, 2016
Commission File
Number: 000-31265
MabVax
Therapeutics Holdings, Inc.
(Exact
name of registrant as specified in its charter.)
|
Delaware
|
93-0987903
|
|
(State or other
jurisdiction of incorporation or organization)
|
(IRS Employer
Identification No.)
|
11535 Sorrento
Valley Rd., Suite 400, San Diego, California
92121
(Address of
principal executive offices)
858-259-9405
(Registrant's
Telephone number)
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation ofthe registrant under
any of the following provisions (see General Instruction A.2.
below):
[ ]
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item
2.02 Results of Operations and Financial Condition.
On
November 10, 2016, we issued a press release reporting our
financial results for the third quarter ended September 30, 2016.
The full text of the press release is furnished as Exhibit 99.1 to
this Current Report on Form 8-K. We also announced that we would
hold a conference call on Monday, November 14, 2016 to provide a
business and financial update, including clinical trial results and
patents issued to the Company.
Item
9.01 Financial Statements and Exhibits.
99.1
Press release issued November 10, 2016, reporting financial results
for the third quarter ended September 30, 2016
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalfby the
undersigned hereunto duly authorized.
|
|
MabVax
Therapeutics Holdings, Inc.
|
|
|
|
|
|
|
|
|
Date: November 10, 2016
|
By:
|
/s/ Gregory P.
Hanson
|
|
|
|
|
Name: Gregory P.
Hanson
|
|
|
|
|
Title: Chief
Financial Officer
|
|
Exhibit
Index
|
Exhibit
No.
|
Description
|
|
|
|
|
EX-99.1
|
Press Release of
the Company dated November 10, 2016
|